Review
Copyright ©The Author(s) 2017.
World J Gastrointest Oncol. Jul 15, 2017; 9(7): 281-292
Published online Jul 15, 2017. doi: 10.4251/wjgo.v9.i7.281
Table 1 Summary of adjuvant studies for early stage pancreatic cancer
Adjuvant systemic therapy
Study[20,22-24,26,27,29]TreatmentTreatment groupControl group

DFS (mo)OS (mo)2 yr survival5 yr survivalDFS (mo)OS (mo)2 yr survival5 yr survival

5-FU based treatments
ESPAC-1 Neoptolemos et al[20], 20015-FU/LV vs observation-19.7---14.0--
ESPAC-1 and 3 pooled analysis Neoptolemos et al[22], 20095-FU/LV vs observation-23.249.0%24.0%-16.837.0%14.0%
Gemcitabine based treatments
CONKO-001, Oettle et al[24], 2007Gemcitabine vs observation13.422.1-16.5%6.920.5-5.5%
JSAP-02, Ueno et al[26], 2009Gemcitabine vs observation11.422.348.3%23.9%5.018.440.0%10.6%
Gemcitabine compared to 5-FU
ESPAC-3, Neoptolemos et al[23], 2010Gemcitabine vs 5-FU/LV14.323.629.6%-14.123.030.7%-
RTOG 97-04, Regine et al[27], 2008Gemcitabine vs 5-FU/LV in patients receiving CRT-20.5---16.9--
Combination treatments
ESPAC-4, Neoptolemos et al[29], 2017Gemcitabine plus capecitabine vs Gemcitabine13.928.053.8%-13.125.552.1%-
Table 2 Summary of first line studies for advanced pancreatic cancer
First line treatment for metastatic disease
Study[41,49,63-67,71]TreatmentTreatment groupControl group

ORRPFS (mo)OS (mo)1 yr SurvivalORRPFS (mo)OS (mo)1 yr Survival

Standard of care
Burris et al[41], 1997Gemcitabine vs 5-FU/LV-9 wk5.6518.0%-4 wk4.012.0%
Conroy et al[49], 2011FOLFIRINOX vs Gemcitabine31.6%6.411.148.4%9.4%3.36.820.6%
Von Hoff et al[71], 2013Nab-paclitaxel plus gemcitabine vs gemcitabine23.0%5.58.535.0%7.0%3.76.722.0%
Gemcitabine doublets
Berlin et al[63], 2002Gemcitabine plus 5-FU vs gemcitabine6.9%3.46.7-5.6%2.25.4-
Herrmann et al[64], 2007Gemcitabine plus capecitabine vs gemcitabine10.0%4.38.432.0%7.8%3.97.230.0%
Moore et al[66], 2007Gemcitabine plus erlotinib vs gemcitabine8.6%3.86.223.0%8.0%3.65.917.0%
Philip et al[67], 2010Gemcitabine plus cetuximab vs gemcitabine12.0%3.46.3-14.0%3.05.9-
Ueno et al[65], 2013Gemcitabine plus S1 vs gemcitabine29.3%5.710.140.7%13.3%4.18.835.4%